Silexion Therapeutics Ltd.
SLXN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $4 | $0 | $0 | $0 |
| Gross Profit | -$4 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,157 | $1,018 | $590 | $1 |
| G&A Expenses | $0 | $1,263 | $1,056 | $12 |
| SG&A Expenses | $1,131 | $1,263 | $1,056 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $3 | $4 | $10 |
| Operating Expenses | $3,288 | $2,284 | $1,650 | $23 |
| Operating Income | -$3,292 | -$2,284 | -$1,650 | -$23 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $30 | -$216 | -$85 | -$8 |
| Pre-Tax Income | -$3,262 | -$2,500 | -$1,735 | -$31 |
| Tax Expense | $0 | $3 | $0 | $0 |
| Net Income | -$3,262 | -$2,503 | -$1,735 | -$31 |
| % Margin | – | – | – | – |
| EPS | 2.88 | 4.32 | -0.26 | -0.19 |
| % Growth | -33.3% | 1,761.5% | -36.8% | – |
| EPS Diluted | 2.88 | 4.32 | -0.26 | -0.19 |
| Weighted Avg Shares Out | 1,133 | 580 | 6,779 | 9,244 |
| Weighted Avg Shares Out Dil | 1,133 | 580 | 6,779 | 9,244 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $43 | $0 | $0 |
| Interest Expense | $0 | $0 | $9 | $0 |
| Depreciation & Amortization | $4 | $3 | $4 | $0 |
| EBITDA | -$3,258 | -$2,497 | -$1,722 | -$23 |
| % Margin | – | – | – | – |